Ascendis Pharma bags YORVIPATH FDA approval for adult hypoparathyroidism

Pallavi Madhiraju- August 12, 2024 0

In a landmark decision, the U.S. Food and Drug Administration (FDA) has granted approval to Ascendis Pharma A/S’s YORVIPATH (palopegteriparatide), making it the first and ... Read More

AstraZeneca to acquire Amolyt Pharma in $1.05bn deal to expand rare disease portfolio

Pallavi Madhiraju- March 15, 2024 0

AstraZeneca has announced a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on novel treatments for rare endocrine diseases, in a deal ... Read More